Alto Neuroscience (ANRO) Operating Income (2023 - 2026)
Alto Neuroscience (ANRO) reported Operating Income of -$27.1 million for Q1 2026, down 73.12% on a YoY basis from -$101.0 million in Q1 2025, and down 59.12% sequentially from -$17.1 million in Q4 2025.
Alto Neuroscience (ANRO) Operating Income (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Operating Income data on file, last reported at -$27.1 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 73.12% year-over-year to -$27.1 million; the trailing twelve-month figure through Mar 2026 stood at -$77.8 million (down 11.34% YoY), and the FY2025 full-year result was -$66.4 million, up 3.27% from the prior year.
- Operating Income eased to -$27.1 million in Q1 2026, from -$17.1 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$7.2 million in Q1 2023 to a low of -$27.1 million in Q1 2026.
- A 4-year average of -$15.4 million and a median of -$15.7 million in 2025 frame the typical range for Operating Income.
- Across the five-year window, Operating Income tumbled 101.0% in 2024 and gained 20.84% in 2025, its largest moves.
- Tracing ANRO's Operating Income over 4 years: stood at -$11.8 million in 2023, then tumbled by 44.47% to -$17.0 million in 2024, then slipped by 0.34% to -$17.1 million in 2025, then tumbled by 59.12% to -$27.1 million in 2026.
- Business Quant data shows ANRO's Operating Income at -$27.1 million in Q1 2026, -$17.1 million in Q4 2025, and -$15.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - | -27.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.14 Mn |
| Dec 31, 2025 | -17.06 Mn |
| Sep 30, 2025 | -14.95 Mn |
| Jun 30, 2025 | -18.68 Mn |
| Mar 31, 2025 | -15.68 Mn |
| Dec 31, 2024 | -17.00 Mn |
| Sep 30, 2024 | -18.89 Mn |
| Jun 30, 2024 | -18.34 Mn |
| Mar 31, 2024 | -14.39 Mn |
| Dec 31, 2023 | -11.77 Mn |
| Sep 30, 2023 | -9.72 Mn |
| Jun 30, 2023 | -9.13 Mn |
| Mar 31, 2023 | -7.20 Mn |